Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › afatinib

afatinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of afatinib

32 trials tracked of afatinib: 9 in phase 3 or 4 and 2 with published results. The most-cited published study has 60 citations.

32Trials tracked
9Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 7 Phase 2 9 Phase 1 6 Other / NA 8
  1. Phase 3 LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed · 60 cited
  2. Phase 3 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Completed · 11 cited
  3. Phase 4 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation Completed
  4. Phase 4 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older Completed
  5. Phase 3 ADAM-Afatinib Diarrhea Assessment and Management Completed
  6. Phase 3 Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations Completed
Show 26 more trials
  1. Phase 3 An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) Completed
  2. Phase 3 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed
  3. Phase 3 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed
  4. Phase 2 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Completed
  5. Phase 2 Afatinib in NSCLC With HER2 Mutation Completed
  6. Phase 2 Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung Completed
  7. Phase 2 LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung Completed
  8. Phase 2 Trial of Afatinib in Pediatric Tumours Completed
  9. Phase 2 Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases Completed
  10. Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed
  11. Phase 2 Afatinib in NSCLC With HER2 Mutation Completed
  12. Phase 2 Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy Completed
  13. Phase 1 Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours Completed
  14. Phase 1 Drug Interaction Study With Rifampicin and Afatinib Completed
  15. Phase 1 Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects Completed
  16. Phase 1 Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. Completed
  17. Phase 1 Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) Completed
  18. Phase 1 Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib Completed
  19. N/A The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer Completed
  20. N/A Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma Completed
  21. N/A Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. Completed
  22. N/A Afatinib Osimertinib Sequencing NIS Completed
  23. N/A GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations Completed
  24. N/A A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel Completed
  25. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed
  26. N/A Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
EGFR p.E709_T710delinsD mutation may present with primary resistance and rapid progression on afatinib
Oncology Sys. Review
EGFR p.E709_T710delinsD mutation may present with primary resistance and rapid progression on afatinib Specific Lung Cancer Mutation May Lead to Rapid Treatment Failure
This case report and literature review describes a patient with stage IV lung adenocarcinoma and an EGFR p.E709_T710delinsD mutation who exp…
A specific mutation in lung cancer may cause patients to progress quickly on afatinib, highlighting the need for early monitoring and testin…
Frontiers Oct 26, 2026
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Genetics & Precision Medicine Phase I
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
May 1, 2026